Tower Research Capital (TRC)’s Outlook Therapeutics OTLK Stock Holding History
Bought
Maintained
Sold
Other funds holding OTLK
Tower Research Capital (TRC)'s OTLK Position: Q3 2026 in Review
Tower Research Capital (TRC) sold out of Outlook Therapeutics (OTLK) in Q3 2026, closing a stake of 57,391 shares — an estimated $91.3K sold.
Tower Research Capital (TRC) first reported a position in OTLK in Q2 2016 and held it in 24 quarters. The position peaked at $139K in Q1 2022. 82 funds tracked by Wall St. Rank hold OTLK as of Q3 2026.
- Tower Research Capital (TRC) reported no remaining Outlook Therapeutics position as of Q3 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 57,391 Outlook Therapeutics shares in Q3 2026, an estimated $91.3K.
- Tower Research Capital (TRC) first reported a position in Outlook Therapeutics in Q2 2016 and held it in 24 quarters.
- Tower Research Capital (TRC)'s Outlook Therapeutics position peaked at $139K in Q1 2022.
- 82 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.